0
Clinical Investigations: RESPIRATORY SYMPTOMS |

Palliative Treatment of Dyspnea With Epidural Methadone in Advanced Emphysema*

Gustavo Juan, MD, PhD; Mercedes Ramón, MD, PhD; Juan Carlos Valia, MD; Julio Cortijo, PhD; Elena Rubio, MD, PhD; Esteban Morcillo, MD, PhD; Peter Calverley, FRCP
Author and Funding Information

*From the Departments of Medicine (Dr. Juan) and Pharmacology (Drs. Rubio and Morcillo), Faculty of Medicine, University of Valencia, Valencia, Spain; Service of Pneumology (Dr. Ramón), Service of Anesthesia (Dr. Valia), and Research Foundation (Dr. Cortijo), University General Hospital, Valencia, Spain; and University Hospital Aintree (Dr. Calverley), Liverpool, UK.

Correspondence to: Gustavo Juan, MD, PhD, Departamento de Medicina, Facultad de Medicina, Avda. Blasco Ibáñez, 15, E-46010 Valencia, Spain; e-mail: Gustavo.Juan@uv.es



Chest. 2005;128(5):3322-3328. doi:10.1378/chest.128.5.3322
Text Size: A A A
Published online

Study objectives: This study investigated whether epidural methadone perfusion at the thoracic level can mitigate dyspnea in patients with advanced emphysema.

Design: Open-label clinical trial without a control group.

Setting: University hospital.

Patients: The inclusion criteria were a diagnosis of emphysema, basal dyspnea index (Mahler scale) ≤ 3, FEV1 ≤ 35%, and no indication for pneumoreduction or lung transplantation surgery.

Interventions: An epidural catheter was inserted at the thoracic level connected to a perfusion pump for administering methadone (6 mg/24 h). Assessments were made at baseline, 1 week, and 1 month after catheter insertion.

Measurements: Pulmonary function tests were performed, and determinations were made of arterial blood gas levels, respiratory control data, dyspnea quantification by Mahler transitional dyspnea index (TDI), and the Borg scale change with inspiratory resistive loading, 6-min walk (6MW) distance, and health-related quality of life using the Chronic Respiratory Disease Questionnaire.

Results: Of the nine patients studied, infection and catheter migration lead to suspension of treatment before the end of the study in two cases. A significant improvement in dyspnea occurred by 1 week: mean TDI, 3.77 (SD, 1.98) [p < 0.01]. After 1 month of treatment, there were significant improvements in the 6MW distance (mean, 35.33 m; SD, 17.03; p < 0.05), health-related quality of life (mean, 1.63; SD, 0.36; p < 0.05), and dyspnea (mean TDI, 5.33; SD, 2.16; p < 0.05). In addition, after 1 month, Paco2 fell by 6.67 mm Hg (p < 0.05) and rapid shallow breathing index decreased from 38 to 27 (p < 0.05). These changes occurred without any alteration in the subject’s ability to perceive or respond to inspiratory loading.

Conclusion: Epidural methadone perfusion at chest level can effectively palliate dyspnea and improve exercise capacity and quality of life in patients with advanced emphysema, without deterioration in respiratory control or lung function. These data suggest that modulation of spinal cord afferent signaling is an appropriate novel target for dyspnea control in chronic respiratory disease.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543